AUR-AF9A-TTM1-A-1-1-R-A742-41
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.570
- G2M_CHECKPOINT+0.470
- GLYCOLYSIS+0.380
- OXIDATIVE_PHOSPHORYLATION+0.350
- DNA_REPAIR+0.340
- MTORC1_SIGNALING+0.340
- MYC_TARGETS_V2+0.280
- WNT_BETA_CATENIN_SIGNALING+0.230
- HYPOXIA+0.220
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.330
- NOTCH_SIGNALING-0.330
- INFLAMMATORY_RESPONSE-0.310
- IL2_STAT5_SIGNALING-0.290
- TNFA_SIGNALING_VIA_NFKB-0.280
- TGF_BETA_SIGNALING-0.270
- COAGULATION-0.240
- ALLOGRAFT_REJECTION-0.220
- MYOGENESIS-0.210
- IL6_JAK_STAT3_SIGNALING-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_4634_T1_RNA | — | E | 0.850 |
| 2 | SRR8518179 | — | E | 0.846 |
| 3 | SRR6013564 | — | cohortSQ2 | 0.846 |
| 4 | TCGA-NC-A5HD-01A-11R-A26W-07 | — | cohortSQ1 | 0.822 |
| 5 | BS_P7EY9DXG | ATRT | — | 0.810 |
| 6 | BS_MV6ASWV9 | ATRT | — | 0.810 |
| 7 | SRR975602 | — | — | 0.808 |
| 8 | C3N-03204 | — | cohortSQ2 | 0.807 |
| 9 | GSM5359432 | — | — | 0.797 |
| 10 | SRR25617920 | — | E | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |